Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Munkholm, E. Langholz, M. Davidsen, V. Binder.
Frequency of glucocorticoid resistence and dependency in Crohn's disease.
Gut, 35 (1994), pp. 360-362
[2.]
R.B. Muijsers, K.L. Goa.
Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Drugs, 62 (2002), pp. 1689-1705
[3.]
R. Pruitt, J. Hanson, M. Safdi, L. Wruble, R. Hardi, J. Johanson, et al.
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Am J Gastroenterol, 97 (2002), pp. 3078-3086
[4.]
W. Kruis, S. Schreiber, D. Theuer, J.W. Brandes, E. Schütz, S. Howaldt, et al.
Low dose balsalazide (1. 5 g twice daily) and mesalazine (0. 5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3 g twice daily) was superior in preventing relapses.
Gut, 49 (2001), pp. 783-789
[5.]
O.O. Thomsen, A. Cortot, D. Jewell, J.P. Wright, T. Winter, F.T. Veloso, et al.
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Am J Gastroenterol, 97 (2002), pp. 649-653
[6.]
A. Levine, E. Broide, M. Stein, Y. Bujanover, Z. Weizman, G. Dinari, et al.
Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children.
J Pediatr, 140 (2002), pp. 75-80
[8.]
M.F. Neurath, R. Wanitschke, M. Peters, F. Krummenauer, K.H. Meyer, J.F. Schlaak.
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease.
Gut, 44 (1999), pp. 625-628
[9.]
W. Miehsler, W. Reinisch, G. Moser, A. Gangl, H. Vogelsang.
Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?.
Am J Gastroenterol, 96 (2001), pp. 782-787
[10.]
T. Orth, M. Peters, J.F. Schlaak, F. Krummenauer, R. Wanitschke, W.J. May, et al.
Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
Am J Gastroenterol, 95 (2000), pp. 1201-1207
[11.]
A. Bousvaros, B.S. Kirschner, S.L. Werlin, L. Parker-Hartigan, F. Daum, K.B. Freeman, et al.
Oral tacrolimus treatment of severe colitis in children.
J Pediatr, 137 (2000), pp. 794-799
[12.]
S.R. Targan, S.B. Hanauer, S.J.H. Deventer, L. Mayer, D.H. Present, T. Braakinan, et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease.
N Engl J Med, 337 (1997), pp. 1029-1035
[13.]
P. Rutgeerts, G. D'Haens, S. Targan, E. Vasiliauskas, S.B. Hanauer, D.H. Present, et al.
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Gastroenterology, 117 (1999), pp. 761-769
[14.]
D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. Van Hogezand, et al.
Infliximab for the treatment of fistulas in patients with Crohn's disease.
N Engl J Med, 340 (1999), pp. 1398-1405
[15.]
R. Baldassano, E. Vasiliauskas, C.P. Braegger.
A multicenter study of infliximab (anti- TNF-alpha antibody) in the treatment of children with active Crohn's disease [abstract].
Gastroenterology, 116 (1999), pp. A665
[16.]
S. Kugathasan, S.L. Werlin, A. Martinez, M.T. Rivera, J.B. Heikenen, D.G. Binion.
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Am J Gastroenterol, 95 (2000), pp. 3189-3194
[17.]
J.S. Hyams, J. Markowitz, R. Wyllie.
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
J Pediatr, 137 (2000), pp. 192-196
[18.]
C. Su, B.A. Salzberg, J.D. Lewis, J.J. Deren, A. Kornbluth, D.A. Katzka, et al.
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Am J Gastroenterol, 97 (2002), pp. 2577-2584
[19.]
P. Mamula, J.E. Markowitz, K.A. Brown, L.B. Hurd, D.A. Piccoli, R.N. Baldassano.
Infliximab as a novel therapy for pediatric ulcerative colitis.
J Pediatr Gastroenterol Nutr, 34 (2002), pp. 307-311
[20.]
M.A. Parsi, J.P. Achkar, S. Richardson, J. Katz, J.P. Hammel, B. Lashner, et al.
Predictors of response to infliximab in patients with Crohn's disease.
Gastroenterology, 123 (2002), pp. 707-713
[21.]
J. Bauditz, S. Wedel, H. Lochs.
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
Gut, 50 (2002), pp. 196-200
[22.]
E.D. Ehrenpreis, S.V. Kane, L.B. Cohen, R.D. Cohen, S.B. Hanauer.
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
Gastroenterology, 117 (1999), pp. 1271-1277
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados